表紙
市場調查報告書

病毒載體市場:2020年∼2024年

Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 917421
出版日期 內容資訊 英文 154 Pages
訂單完成後即時交付
價格
病毒載體市場:2020年∼2024年 Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年11月12日內容資訊: 英文 154 Pages
簡介

全球病毒載體市場上,慢性疾病的盛行率上升,基因治療和疫苗開發上病毒載體的使用增加,對基因治療及疫苗的資金和投資擴大等成為成長促進因素,在預測期間內預計將以18%以上的年複合成長率擴大。但,病毒載體的生產與製造相關的課題,嚴格的法規政策的存在,及病毒載體相關的風險,有可能妨礙在預測期間內病毒載體產業的成長。

本報告提供全球病毒載體市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析
  • 價值鏈分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模與預測(2019年∼2024年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模與預測(2019年∼2024年)
  • 基因治療
  • 疫苗
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 基因治療開發的研究開發活動的增加
  • 使用了病毒載體的疫苗
  • M&A與合作的增加
  • 為了製造病毒載體的新技術登場

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Asklepios BioPharmaceutical Inc.
  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • Novasep Holding SAS
  • Oxford Biomedica Plc
  • Thermo Fisher Scientific Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40121

About this market

Technavio's viral vectors market analysis considers sales from both gene therapy and vaccines applications. Our study also finds the sales of viral vectors in Asia, Europe, North America, and ROW. In 2019, the gene therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy purification into high titers to mediate targeted gene delivery and its prolonged gene expression with nominal side effects will play a significant role in the gene therapy segment to maintain its market position. Also, our global viral vectors market report looks at factors such as rising prevalence of chronic diseases, increasing use of viral vectors to develop gene therapies and vaccines, and growing funding on and investments in gene therapies and vaccines. However, challenges associated with production and manufacturing of viral vectors, presence of stringent regulatory policies, and risks associated with viral vectors may hamper the growth of the viral vectors industry over the forecast period.

Overview

Rising prevalence of chronic disease

The development of therapies using viral vectors is in high demand due to the growing incidence of various life-threatening diseases such as diabetes, heart disease, HIV, cancer, and hemophilia A. Researchers are using viral vectors to develop curative therapies for cancer diseases such as bladder cancer, melanoma of the skin, lung and bronchus cancer, and other types of cancers. This is because viral vectors are a promising tool for the development of vaccines and gene therapy. Thus, the rising prevalence of chronic disease will lead to the expansion of the global viral vectors market at a CAGR of over 18% during the forecast period.

Emergence of novel technologies to manufacture viral vectors

The use of viral gene transfer vectors has increased owing to the approval of therapies, the initiation of late-stage clinical trials for the treatment of genetic disorders and multiple forms of cancer, and the need for the prevention of infectious diseases through vaccination. With an increased interest in and the widespread adoption of viral vectors by biopharmaceutical industries, there is a need to engineer safe and efficacious vectors and develop robust, scalable, and cost-effective production platforms for industrialization. Furthermore, adeno-associated virus vectors are among most commonly applied virus vectors for in vivo gene therapy as they can transduce non-dividing and dividing cells resulting in long-term and robust transgene expression. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global viral vectors market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of a few major players, the global viral vectors market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading viral vectors manufacturers, that include Asklepios BioPharmaceutical Inc., Batavia Biosciences BV, Cobra Biologics Ltd., Creative Biogene, FinVector Oy, Lonza Group Ltd., Merck KGaA, Novasep Holding SAS, Oxford Biomedica Plc, and Thermo Fisher Scientific Inc.

Also, the viral vectors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Gene therapy - Market size and forecast 2019-2024
  • Vaccines - Market size and forecast 2019-2024
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing number of R&D activities for development of gene therapies
  • and vaccines using viral vectors
  • Rising number of M&A and collaborations
  • Emergence of novel technologies to manufacture viral vectors

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Asklepios BioPharmaceutical Inc.
  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • Novasep Holding SAS
  • Oxford Biomedica Plc
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global healthcare market
  • Exhibit 03: Segments of global healthcare market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Application - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Gene therapy - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Gene therapy using adenovirus vectors
  • Exhibit 22: Gene therapy using adeno-associated virus vectors
  • Exhibit 23: Gene therapy using lentivirus vectors
  • Exhibit 24: Gene therapy - Year-over-year growth 2020-2024 (%)
  • Exhibit 25: Vaccines - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 26: Vaccines - Year-over-year growth 2020-2024 (%)
  • Exhibit 27: Market opportunity by application
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2019-2024 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Asklepios BioPharmaceutical Inc. - Vendor overview
  • Exhibit 52: Asklepios BioPharmaceutical Inc. - Product segments
  • Exhibit 53: Asklepios BioPharmaceutical Inc. - Organizational developments
  • Exhibit 54: Asklepios BioPharmaceutical Inc. - Key offerings
  • Exhibit 55: Asklepios BioPharmaceutical Inc. - Key customers
  • Exhibit 56: Batavia Biosciences BV - Vendor overview
  • Exhibit 57: Batavia Biosciences BV - Product segments
  • Exhibit 58: Batavia Biosciences BV - Organizational developments
  • Exhibit 59: Batavia Biosciences BV - Key offerings
  • Exhibit 60: Batavia Biosciences BV - Key customers
  • Exhibit 61: Cobra Biologics Ltd. - Vendor overview
  • Exhibit 62: Cobra Biologics Ltd. - Product segments
  • Exhibit 63: Cobra Biologics Ltd. - Organizational developments
  • Exhibit 64: Cobra Biologics Ltd. - Key offerings
  • Exhibit 65: Cobra Biologics Ltd. - Key customers
  • Exhibit 66: Creative Biogene - Vendor overview
  • Exhibit 67: Creative Biogene - Business segments
  • Exhibit 68: Creative Biogene - Key offerings
  • Exhibit 69: Creative Biogene - Key customers
  • Exhibit 70: FinVector Oy - Vendor overview
  • Exhibit 71: FinVector Oy - Service segments
  • Exhibit 72: FinVector Oy - Key offerings
  • Exhibit 73: FinVector Oy - Key customers
  • Exhibit 74: Lonza Group Ltd. - Vendor overview
  • Exhibit 75: Lonza Group Ltd. - Business segments
  • Exhibit 76: Lonza Group Ltd. - Organizational developments
  • Exhibit 77: Lonza Group Ltd. - Geographic focus
  • Exhibit 78: Lonza Group Ltd. - Segment focus
  • Exhibit 79: Lonza Group Ltd. - Key offerings
  • Exhibit 80: Lonza Group Ltd. - Key customers
  • Exhibit 81: Merck KGaA - Vendor overview
  • Exhibit 82: Merck KGaA - Business segments
  • Exhibit 83: Merck KGaA - Organizational developments
  • Exhibit 84: Merck KGaA - Geographic focus
  • Exhibit 85: Merck KGaA - Segment focus
  • Exhibit 86: Merck KGaA - Key offerings
  • Exhibit 87: Merck KGaA - Key customers
  • Exhibit 88: Novasep Holding SAS - Vendor overview
  • Exhibit 89: Novasep Holding SAS - Business segments
  • Exhibit 90: Novasep Holding SAS - Organizational developments
  • Exhibit 91: Novasep Holding SAS - Key offerings
  • Exhibit 92: Novasep Holding SAS - Key customers
  • Exhibit 93: Oxford Biomedica Plc - Vendor overview
  • Exhibit 94: Oxford Biomedica Plc - Business segments
  • Exhibit 95: Oxford Biomedica Plc - Organizational developments
  • Exhibit 96: Oxford Biomedica Plc - Geographic focus
  • Exhibit 97: Oxford Biomedica Plc - Segment focus
  • Exhibit 98: Oxford Biomedica Plc - Key offerings
  • Exhibit 99: Oxford Biomedica Plc - Key customers
  • Exhibit 100: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 101: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 102: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 103: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 104: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 105: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 106: Thermo Fisher Scientific Inc. - Key customers
  • Exhibit 107: Validation techniques employed for market sizing
  • Exhibit 108: Definition of market positioning of vendors